| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -208,518 | -128,225 |
| Depreciation and amortization | 333 | 204 |
| Accretion of discount and amortization of premium on debt securities, net | -5,872 | -4,421 |
| Accretion of loan exit fee and amortization of loan costs, net | 1,220 | 377 |
| Reduction in the carrying amount of operating lease right-of-use assets | 1,336 | 901 |
| Stock-based compensation | 26,961 | 17,216 |
| Payment of vt-109 license fee | 800 | 800 |
| Prepaid expense and other current assets | 3,556 | 4,162 |
| Other assets | -50 | -158 |
| Accounts payable | 10,285 | 5,492 |
| Accrued and other liabilities | 7,234 | 3,319 |
| Operating lease liabilities | -1,383 | -863 |
| Net cash used in operating activities | -171,110 | -109,204 |
| Payment of vt-109 license fee | 800 | 800 |
| Proceeds from maturities of marketable securities | - | 232,307 |
| Purchase of property and equipment | 528 | 395 |
| Purchase of marketable securities | 285,947 | 187,251 |
| Proceeds from maturities of marketable securities | 400,897 | - |
| Proceeds from sale of marketable securities | 0 | 0 |
| Net cash provided by (used in) investing activities | 113,622 | 43,861 |
| Proceeds from exercise of stock options and employee stock purchase plan | 2,794 | 1,997 |
| Proceeds from refinancing under loan and security agreement, net | 23,338 | 23,338 |
| Payment of deferred issuance costs related to unfunded loan commitments | 3,517 | 3,517 |
| Proceeds from short swing settlement | 0 | 0 |
| Repurchase of common stock | 0 | - |
| Proceeds from issuance of common stock in follow-on offering | 0 | 0 |
| Payment of issuance costs and underwriting fees related to follow-on offering | 0 | 0 |
| Net cash provided by financing activities | 22,615 | 21,818 |
| Net decrease in cash and cash equivalents | -34,873 | -43,525 |
| Cash and cash equivalents at beginning of period | 92,646 | - |
| Cash and cash equivalents at end of period | 57,773 | - |
Vera Therapeutics, Inc. (VERA)
Vera Therapeutics, Inc. (VERA)